Rein Therapeutics Inc.
RNTXNASDAQHealthcareBiotechnology
Latest quote
$0.8252
+$0.0244 · +3.07%
RNTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
24
Weakening
Sentiment
42
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- James Brian Windsor
- Listed since
- Jun 29, 2017
- Employees
- 10
Market position
- Volume
- 583.53K
- 0.71× average
- Average volume
- 816.45K
- Average daily volume
- Market cap
- 22.87M USD
- Beta
- 1.37
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 26.3M USD
- P/E (TTM)
- -0.48×
- P/B (TTM)
- 5.38×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.52×
- Earnings yield
- -168.96%
- Free cash flow yield
- -65.60%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -294.78%
- Return on assets
- -206.44%
- Return on invested capital
- -120.27%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.7×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1K USD | — | — | — | — |
| Gross profit | −1K USD | — | — | — | — |
| Research and development | 11.03M USD | 14.25M USD | 3.99K USD | 17.97K USD | 17.01K USD |
| Selling, general, and administrative | 10.9M USD | 13.86M USD | 11.36K USD | 9.68K USD | 9.6K USD |
| Operating expenses | 21.93M USD | 65.11M USD | 16.28K USD | 27.65K USD | 26.61K USD |
| Interest income | — | 400K USD | 600 USD | — | — |
| Depreciation and amortization | 1K USD | 63K USD | 119 USD | 169 USD | 121 USD |
| Operating income | −21.93M USD | −65.11M USD | −16.28K USD | −27.65K USD | −26.61K USD |
| Net income | −49.87M USD | −62.88M USD | −15.73K USD | −27.33K USD | −26.16K USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 7 misses, 1 met estimate
- Average EPS surprise
- -159.19%
- 11 comparable reports
- Latest EPS result
- -0.1
- Estimate -0.17 · Beat by 41.18%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$6.00
633.50% upsideRecent analyst actions
RNTX news
RNTX peers
ETFs holding RNTX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research RNTXresearch.disclaimer